Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.

Transthyretin depletion for treatment of hereditary systemic and senile cardiac amyloidosis (360G-Wellcome-082989_Z_07_B)

Systemic transthyretin amyloidosis is a fatal late onset disease caused by tissue deposition of amyloid fibrils composed of variant and wild type transthyretin. The objective of the project is to construct compounds to trigger the accelerated clearance of plasma transthyretin molecules by the liver by synthesising palindromic ligand-linker-ligand compounds capable of cross-linking transthyretin molecules or oligosaccharide-ligand conjugates that direct hepatic clearance, which could be used as drugs for treating and preventing acquired and hereditary human systemic transthyretin amyloidosis. The aim is to optmise the design, synthesis, and properties of a transthyretin depleting drug and complete the comprehensive safety and efficacy evaluation required prior to administration of a validated candidate compound in humans.

£610,617

19 Dec 2008

Grant details
Amount Awarded 610617
Applicant Surname Pepys
Approval Committee Seeding Drug Discovery Committee
Award Date 2008-12-19T00:00:00+00:00
Financial Year 2008/09
Grant Programme: Title Seeding Drug Discovery Award
Internal ID 082989/Z/07/B
Lead Applicant Prof Sir Mark Pepys
Planned Dates: End Date 2009-01-30T00:00:00+00:00
Planned Dates: Start Date 2008-07-31T00:00:00+00:00
Recipient Org: Country United Kingdom
Region Greater London
Additional data added by GrantNav